ANI Pharmaceuticals ANIP Gain on retained interest in Sandisk
Gain on retained interest in Sandisk at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's gain on retained interest in sandisk.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's gain on retained interest in sandisk?
- ANI Pharmaceuticals (ANIP) reported gain on retained interest in sandisk of $5.75M in Q1 2026.
- How has ANI Pharmaceuticals's gain on retained interest in sandisk changed year-over-year?
- ANI Pharmaceuticals's gain on retained interest in sandisk increased by 724.6% year-over-year, from -$921K to $5.75M.
- What does gain on retained interest in sandisk mean?
- This metric reflects the unrealized gains or losses resulting from changes in the fair market value of equity investments held by the company. It captures the impact of market volatility on the company's non-core investment portfolio rather than its primary pharmaceutical operations. Investors use this to distinguish between core operational performance and gains or losses driven by external financial market fluctuations.